Qsymia vs. Contrave

Are Qsymia and Contrave the same drug?

No — they are entirely different two-drug combinations with different mechanisms. Qsymia pairs phentermine (an appetite-suppressing stimulant) with topiramate (an antiseizure drug that also reduces appetite). Contrave pairs naltrexone (an opioid-receptor blocker) with bupropion (an antidepressant).

Both are FDA-approved pills for long-term weight management, but they suppress appetite through different brain pathways and carry very different safety profiles [1], [2].

Where these fit alongside GLP-1 medications

Both are daily oral tablets, not GLP-1 drugs like Wegovy, Zepbound, or the oral GLP-1 pills Rybelsus and Foundayo. They generally produce less weight loss than the GLP-1 class, but they have a long track record and cost far less — which makes them a practical option for people who can't take or can't afford a GLP-1, or would rather not start one [1], [2].

Like every weight medication, they are meant to be used with a reduced-calorie diet and increased activity, and the weight tends to return if the drug is stopped.

What is Qsymia?

Qsymia (phentermine/topiramate extended-release) is a once-daily capsule FDA-approved for chronic weight management. It is taken in the morning and titrated from a starting dose of 3.75/23 mg up to a maximum of 15/92 mg. Because it contains phentermine, Qsymia is a Schedule IV controlled substance.

In its pivotal trial, CONQUER, the top dose produced a mean −9.8% of body weight at 56 weeks, versus −1.2% on placebo [1], [3].

What is Contrave?

Contrave (naltrexone/bupropion extended-release) is an oral tablet, taken twice daily, FDA-approved for chronic weight management. It is titrated over four weeks up to a maintenance dose of two tablets twice daily (32 mg naltrexone / 360 mg bupropion total). It is not a controlled substance.

In its pivotal trial, COR-I, Contrave produced a mean −6.1% of body weight at 56 weeks, versus −1.3% on placebo [2], [4].

How they work

Qsymia suppresses appetite directly: phentermine reduces hunger through stimulant-like signaling, while topiramate promotes a feeling of fullness (its exact weight effect isn't fully understood) [1].

Contrave works on the brain's appetite and reward systems: bupropion stimulates appetite-regulating neurons while naltrexone blocks a feedback loop that would otherwise blunt that effect, which together reduce hunger and food cravings [2]. The practical upshot: Qsymia leans on stimulant appetite suppression, Contrave on craving and reward control.

Effectiveness: which produces more weight loss?

Qsymia produced more weight loss in its trials, but there is no head-to-head study pitting the two drugs directly. Comparing their pivotal trials, Qsymia's top dose reached −9.8% of body weight at 56 weeks (CONQUER), while Contrave's top dose reached −6.1% (COR-I) [3], [4].

Because these were separate trials with different participants, the gap is an approximation rather than a direct contest — but the pattern is consistent: Qsymia is generally the more effective of the two for weight loss. Both, in turn, produce less weight loss than GLP-1 drugs such as Wegovy or Zepbound, and individual response varies widely.

What to expect: timeline

Both drugs are titrated up over several weeks, and both have a built-in "is it working?" checkpoint.

With Qsymia, if you haven't lost at least 3% of your weight after 12 weeks on the 7.5/46 dose, the label advises either stopping or escalating to the top dose; if the top dose hasn't produced at least 5% after another 12 weeks, it should be stopped gradually [1].

With Contrave, if you haven't lost at least 5% of your weight after about 12 weeks at the full maintenance dose, the label advises stopping, because continued benefit is unlikely [2]. Either way, weight loss is gradual and depends heavily on pairing the medication with diet and activity.

Dosing & administration

Qsymia dosing

One capsule each morning: 3.75/23 mg (14 days) → 7.5/46 mg → titrate as needed to 11.25/69 → 15/92 mg maximum. Taking it in the morning helps limit insomnia [1].

Contrave dosing

Tablets are increased weekly over four weeks to a maintenance dose of two tablets twice daily. Avoid taking it with high-fat meals, which raise drug levels [2].

Side effects & safety

This is where the two drugs differ most, and where the choice is often made. Their common side effects are different in character, and so are the serious risks and the people who should avoid each [1], [2].

Common side effects

Qsymia: tingling in the hands and feet (paresthesia), dry mouth, altered taste (especially of carbonated drinks), trouble sleeping, constipation, and dizziness. Contrave: nausea, constipation, headache, vomiting, dizziness, and insomnia [1], [2].

Serious risks

Contrave carries a boxed warning for suicidal thoughts and behaviors (from its antidepressant component, bupropion) and can lower the seizure threshold, raise blood pressure and heart rate, and cause liver injury [2].

Qsymia has no boxed warning, but topiramate can cause birth defects, mood and cognitive effects (trouble with memory, concentration, and language), a fast heart rate, acute glaucoma, metabolic acidosis, and kidney stones, and phentermine can raise blood pressure and heart rate [1]. Both can cause low blood sugar in people also taking diabetes medicines.

Who should not take these (and key cautions)

Qsymia is contraindicated in pregnancy — topiramate increases the risk of cleft lip and palate, so anyone who could become pregnant needs effective contraception and pregnancy testing before and during treatment. It is also off-limits with glaucoma, overactive thyroid, or use of an MAOI [1].

Contrave is contraindicated with uncontrolled high blood pressure, a seizure disorder, eating disorders (bulimia or anorexia), chronic opioid use, MAOI use, and pregnancy — and because naltrexone blocks opioids, it can't be combined with opioid pain medicines [2].

Share your full history, medication list, and pregnancy plans with your clinician before starting either drug.

Cost & insurance coverage

Both are far cheaper than GLP-1 medications — typically around $100 a month with a manufacturer savings program, and somewhat more without one. Insurance coverage for weight-loss medication is inconsistent, so the savings programs often matter more than the list price.

A supervised medical weight-loss program like JumpstartMD's can help you compare real out-of-pocket costs and match the medication to your budget and health profile.

Can you switch between them?

Yes — switching is common and is done under medical supervision. People often try one and move to the other for tolerability, effectiveness, or safety reasons — for example, switching off Qsymia when planning a pregnancy, or off Contrave if it isn't tolerated.

Because the drugs are unrelated, a clinician will stop one and start the other at its own starting dose rather than converting between them, and will re-check for any interactions with your other medicines.

Which is right for you?

• You want the greater weight-loss effect → Qsymia produced more weight loss in trials [3], [4].
• You are or could become pregnant → avoid Qsymia (topiramate birth-defect risk); both are contraindicated in pregnancy [1], [2].
• You have a seizure history or take opioids → avoid Contrave [2].
• You struggle with cravings or emotional eating → Contrave's action on reward pathways may be a better mechanistic fit, though response varies [2].

The right choice depends on your weight-loss goal, medical history, other medications, and pregnancy plans — exactly what a supervised consultation sorts out. JumpstartMD physicians prescribe and manage both Qsymia and Contrave (as well as GLP-1 options), including dose titration and side-effect management.